EMEA grants Kiadis Pharma lead product ATIR™ orphan drug designation
Sep 22nd 2008
Kiadis Pharma announced today that its lead product ATIR™ has been granted orphan drug designation (ODD) by the European Medicines Agency (EMEA) for...
read more 
(NL version)
(NL version)
Kiadis Pharma announces collaboration with the Julius Maximilians University of Würzburg, Germany. Dr. Mielke continues his collaboration with Kiadis Pharma on ATIR™
May 29th 2008
Biopharmaceutical company Kiadis Pharma announces today the clinical development collaboration for its lead product ATIR™ with Dr. Stephan Mielke and...
read more (NL version)
(NL version)
- Kiadis Pharma receives Orphan Drug Designation for Rhitol™ from the FDA - Apr 15th 2008 (NL)
- Promising clinical data from Kiadis Pharma’s lead product ATIR™ presented by NIH investigators - Mar 25th 2008 (NL)
- Kiadis Pharma obtains FDA approval to start a phase III clinical trial for Reviroc™ in the United States. FDA approves IND application for Reviroc™ - Feb 22nd 2008 (NL)
- Kiadis Pharma announces successful completion of Rhitol™ Phase II clinical study - Jan 31st 2008 (NL)
- Kiadis Pharma reports successful End of Phase II Meeting with FDA for Reviroc; the FDA offers Special Protocol Assesment for Reviroc - Dec 19th 2007 (NL)
1096 EG Amsterdam
The Netherlands
t +31 (0)20 314 02 50
f +31 (0)20 314 02 51
Zernikepark 6-8
9747 AN Groningen
The Netherlands
t +31 (0) 50 547 42 70
f +31 (0) 50 547 42 71
2525 ave. Marie-Curie
Saint-Laurent (Quebec)
Canada H4S 2E1
t +1 (514) 336-4886
f +1 (514) 336-7329